Camille Callais arrived on the St. Jude campus just as the institution launched an initiative to address pediatric neurological diseases.
The Pediatric Translational Neuroscience Initiative (PTNI) grew from a blue-sky idea, an enterprising suggestion from a St. Jude employee that goes through a formal process to be adopted by the institution, into a pillar of the FY22-27 St. Jude Strategic Plan. In 2020, Richard Finkel, MD, joined the institution to lead the Center for Experimental Neurotherapeutics (CENT) within PTNI, a program designed to advance cures for children with catastrophic neurological diseases. Camille and her parents are experiencing the impact of this effort.
![Camille Callais with her parents](/content/sites/www/en_US/home/about-st-jude/stories/making-a-difference/patient-story-camille-callais/jcr:content/par-1/cnt_row/par-1/cnt_column/par-1/cnt_image.img.16.medium.jpg/1704737774615.jpg)
Casie, Camille and Brandon Callais
Camille has type 2 spinal muscular atrophy (SMA), a genetic condition that leads to muscle weakness that worsens over time. SMA is caused by a mutation in the SMN1 gene, which codes for a protein (SMN) that is critical for normal motor neuron function and survival. Clinician scientists at St. Jude are evaluating the use of SMN-enhancing therapies to stop or slow SMA progression.
Camille is currently enrolled in a clinical trial, DEVOTE, to evaluate the use of an SMN-enhancing drug. Her parents, Brandon and Casie, have already seen improvements in Camille since she started the first round of the trial.
![Dr. Finkel and Camille](/content/sites/www/en_US/home/about-st-jude/stories/making-a-difference/patient-story-camille-callais/jcr:content/par-1/cnt_row/par-1/cnt_column/par-1/cnt_image_211634708.img.16.medium.jpg/1704737822765.jpg)
Dr. Richard Finkel and Camille Callais
“We are thankful that St. Jude is venturing into neuromuscular disorders, and we are happy to be part of a study that can not only help our daughter but also help others with similar disorders,” Casie said.
Finkel is similarly optimistic about the prospect of the clinical research being conducted in CENT.
“Although Camille has been able to stand for some time, she has never been able to walk,” he said. "She is currently on the cusp of walking, and I want to be there for her first step."
For decades, St. Jude clinicians and researchers have sought cures for catastrophic diseases such as cancer, sickle cell and HIV. The institution’s scientific expertise, infrastructure and clinical experience make St. Jude uniquely suited to address pediatric neurological diseases like SMA and help patients like Camille.
![Camille Callais w/Dr. Finkel and her parents](/content/sites/www/en_US/home/about-st-jude/stories/making-a-difference/patient-story-camille-callais/jcr:content/par-1/cnt_row/par-1/cnt_column/par-1/cnt_image_471746254.img.16.medium.jpg/1704737783505.jpg)
Dr. Richard Finkel with Camille Callais, her father Brandon and mother Casie.
More patient stories
-
Insights Learned Through Cancer Experience Now Help Others
St. Jude survivor Tristan Elsener has survived multiple bouts of cancer. He and his family have gained insights that can help others. Learn about the Caregivers Share podcast.
-
Participating in clinical trials to help cure the next person
Patients like Corey Luellen have benefitted from gene editing for sickle cell disease. Luellen participated in a clinical trial for the treatment because he wanted to help others.
-
Patient finds support, help and hope for Friedrich’s ataxia
Taylor Hurdle is taking part in a clinical trial for Friedreich’s ataxia at St. Jude Children’s Research Hospital.
-
Patient reflects on 60th anniversary as childhood cancer survivor
Patient reflects on her 60th anniversary as a childhood cancer survivor
-
Finding Hope in Clinical Trials
A medulloblastoma clinical trial offered hope to 7-year-old Kinlee Johnson and her family. Learn more.
-
From Pain Crises to Good Vibes
Rashawn Hendrix
-
Family chooses St. Jude because of SAMD9/SAMD9L researcher
Family chooses St. Jude for care because of its expertise in SAMD9/SAMD9L syndrome.
-
Molecular diagnostics give Fletcher what some thought impossible: a diagnosis and treatment plan
Molecular diagnostics give Fletcher Fazenbaker what some thought impossible: a diagnosis and treatment plan for infant-type hemispheric glioma (IHG), a subtype of high-grade glioma — a rare brain tumor — that was not classified by the World Health Organization’s brain tumor classification guide until 2021
-
Surviving childhood cancer is just the beginning of Darshana’s story
Darshana Magan survived cancer 30 years ago, but her treatment caused long-term health issues. Read how she cares for her health and encourages other survivors.
-
Sickle cell disease education and support help Jayden excel
Jayden's care team at St. Jude is helping him manage and understand his sickle cell disease. Learn more
-
Scan-tastic! St. Jude helps Zara succeed
St. Jude child life specialists help patients understand the MRI scanning process to make it easier for them, and some patients are able to stay still enough for scans that anesthesia isn't needed.
-
Teen climbs new heights after bone cancer
Doctors at St. Jude Children's Research Hospital were able to save Micah Winkle's leg from bone cancer, but it was up to the teen to discover alternatives to the contact sports he had played before his cancer diagnosis. Find out more.
-
Limiting the side effects of treatment: Proton Therapy provides focused radiation
St. Jude has the world’s first proton therapy center dedicated to childhood cancer. Patients come from all over to receive treatment. One such patient is Brianna Gonzales.